The Record... (cont'd)
Sharon,
I was wondering if you needed any of the articles listed as References at the end of the Adis Record. I can get summaries of articles easily from another database on Dialog—File 173, Adis Clinical Trials Insight.
I'll send you one article so you can see what File 173 offers.
Ric
To find key clinical summaries in the research literature to the drug in question, you can use a special Dialog technique called the MAP command. It enables you to extract data from the cross-reference field XR in File 107 and MAP it to File 173 (or the subscriber file 973), Adis Clinical Trials Insight.
Adis Clinical Trials Insight was reloaded in late 2006, with new fields to let you pick exactly the information you need. Updated weekly, this file is the only place to retrieve data about ongoing trials, as well as presented and published data in a single, searchable database.
It contains highly structured records of key papers, published in more than 1,300 international medical and biomedical journals, papers presented at 100 meetings and clinical data from media releases and relevant company and trial registry web sites on drugs, drug therapy, adverse drug reactions, and pharmacoeconomics. Document types include Best Evidence, Supporting Evidence and Ongoing Trial records.
Tip 4-5Go to the next page after looking at the references below.
References:
1. Bayer AG. Takeover Offer Completed; Bayer Controls 92.4 Percent of Outstanding Schering Shares. Media Release. : 12 Jul 2006. Available from: URL: http://www.bayer.com. (English).
2. Bayer. Renaming of Schering entered in the commercial register: Bayer Schering Pharma AG officially launched. Media Release. : 29 Dec 2006. Available from: URL: http://www.bayer.com. (English).
3. Novartis Pharma AG. Ad hoc: Novartis and Schering AG finalize commercialization agreement. Media Release. : 25 Jan 2005. Available from: URL: http://www.novartis.com. (English).
4. Spectrum Health Cancer Center. Spectrum Health Seeks Patients With Metastatic Colorectal Cancer For Study Of New Drug. Media Release. : 29 Sep 2003. Available from: URL: http://www.spectrum-health.org. Summary in 2 parts (Part A). (English). 809026001
5. Schering AG, Novartis Pharma AG. PTK/ZK CONFIRM 1 Phase III Study Shows Positive Drug Effects in Metastatic Colorectal Cancer - Filing Now Anticipated for Early 2007. Media Release. : 21 Mar 2005. Available from: URL: http://www.schering.de. (English). 809046771
6. Novartis. Novartis/Schering AG Oral Angiogenesis Inhibitor PTK/ZK Completes Enrollment for Key Phase III Metastatic Colorectal Cancer Trial. Media Release. : 3 Jun 2004. Available from: URL: http:// www.novartis.com. (English). 809035481
7. Schering AG. Oral Angiogenesis Inhibitor Enters Phase III Trials for Treatment of Patients With Metastatic Colorectal Cancer. Media Release. : 2 Apr 2003. Available from: URL: http://www.schering.de. (English).
8. Schering AG, Novartis Pharma AG. Planned Interim Analysis of CONFIRM 2 Trial of PTK/ZK Indicates Low Probability of Demonstrating Overall Survival Benefit in Second-Line Therapy of Metastatic Colorectal Cancer. Media Release. : 28 Jul 2005. Available from: URL: http://www.schering.de. (English).
9. Schering AG. New Phase II Clinical Study of PTK/ZK in Lung Cancer. Media Release. : 2 Mar 2005. Available from: URL: http:// www.schering.de. (English). 809045949
10. Schroeder W, Abadie S, et al. Antiangiogenesis as new treatment modality in ovarian cancer: a phase Ib, open label, safety and pharmacokinetics study of escalating doses of PTK787/ZK222584 in combination with paclitaxel and carboplatin in patients with stage IC to IV epithelial ovarian cancer. EJC Supplements. 3: 273 (plus poster) abstr. 949, No. 2, Oct 2005. (English).
11. Pavel M, Schuppan D, et al. A phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients. EJC Supplements. 3: 427 (plus poster) abstr. 1474, No. 2, Oct 2005. (English).
12. Drevs J, Mross K, et al. Phase I dose escalation, pharmacokinetic study of a novel vascular endothelial growth factor receptor inhibitor, PTK787/ZK 222584. European Journal of Cancer. 35 (Suppl. 4): 283, Sep 1999. (English). 800771670
13. Yung WA, Friedman H, et al. A phase I trial of PTK787/ZK 222584, a novel oral VEGFR TK inhibitor in recurrent glioblastoma. 38th Annual Meeting of the American Society of Clinical Oncology. 21: 79, Part 1, 18 May 2002. (English). 800883518
14. Roboz GH, List AF, et al. Phase I trial of PTK787/ZK 222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in acute myeloid leukemia and myelodysplastic syndrome. Blood. 100: 337, Part 1, 16 Nov 2002. (English). 800930484
15. George D, Michaelson D, et al. Phase I study of PTK787/ZK 222584 in metastatic renal cell carcinoma. 39th Annual Meeting of the American Society of Clinical Oncology. : 385 (plus poster) abstr. 1548, 31 May 2003. (English). 800947090
16. Drevs J, Mross K, et al. Phase I dose-escalation and pharmacokinetic study of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases. 39th Annual Meeting of the American Society of Clinical Oncology. : 284 (plus poster) abstr. 1142, 31 May 2003. (English). 800949391
17. Trarbach T, Thomas AL, et al. Preliminary phase I results of the oral, once-daily angiogenesis inhibitor PTK787/ZK 222584 in combination with chemotherapy for the treatment of metastatic colorectal cancer. EJC Supplements. 1: 91 (plus poster) abstr. 297, No. 5, Sep 2003. (English). 800955761
18. Vanhoefer U, Trarbach T, et al. Phase I/II study of PTK787/ZK 222584, a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. Annals of Oncology. 15 (Suppl. 3): 94-95 (plus poster) asbtr.352P, 2004. (English). 800983687
19. Drevs J, Hofmann I, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Research. 60: 4819-4824, 1 Sep 2000. (English).
20. Wood JM, Bold G, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Research. 60: 2178-2189, 15 Apr 2000. (English).
21. Knoblich J, Paldanius PM, et al. Clinical results from an ADME (absorption, distribution, metabolism, and excretion) trial of PTK787/ZK 22284: a novel, oral angiogenesis inhibitor in patients with advanced cancer. EJC Supplements. 1: 170, No. 5, Sep 2003. (English).
22. Xu L, Herrera CA, et al. Therapy of VEGF-dependent human ovarian carcinoma by oral administration of CGP 79787/ZK222584, an inhibitor of the VEGF receptor tyrosine kinase. 90th Annual Meeting of the American Association for Cancer Research. : 457, 10 Apr 1999. (English). 800743129
23. Solorzano CC, Baker CH, et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biotherapy and Radiopharmaceuticals. 16: 359-370, Oct 2001. (English).
24. Lin B, Podar K, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Research. 62: 5019-5026, 1 Sep 2002. (English).
25. Yung WKA, Friedman H, et al. A phase I trial of single-agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme. 39th Annual Meeting of the American Society of Clinical Oncology. : 99 (plus oral presentation) abstr. 395, 31 May 2003. (English). 800897867
26. Reardon D, Friedman HS, et al. A phase I trial of PTK787/ZK 222584, an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme. 39th Annual Meeting of the American Society of Clinical Oncology. : 103 (plus poster) abstr. 412, 31 May 2003. (English). 800897868
27. Drevs J, Steward WP, et al. Biomarkers (VEGF, BFGF) for assessing the biolgoical activity of PTK787/ZK222584, a vascular endothelial growth factor (VEGF) receptor inhibitor, in tumours known to overexpress VEGF. European Journal of Cancer. 38 (Suppl. 7): 78, Nov 2002. (English).
1. Bayer AG. Takeover Offer Completed; Bayer Controls 92.4 Percent of Outstanding Schering Shares. Media Release. : 12 Jul 2006. Available from: URL: http://www.bayer.com. (English).
2. Bayer. Renaming of Schering entered in the commercial register: Bayer Schering Pharma AG officially launched. Media Release. : 29 Dec 2006. Available from: URL: http://www.bayer.com. (English).
3. Novartis Pharma AG. Ad hoc: Novartis and Schering AG finalize commercialization agreement. Media Release. : 25 Jan 2005. Available from: URL: http://www.novartis.com. (English).
4. Spectrum Health Cancer Center. Spectrum Health Seeks Patients With Metastatic Colorectal Cancer For Study Of New Drug. Media Release. : 29 Sep 2003. Available from: URL: http://www.spectrum-health.org. Summary in 2 parts (Part A). (English). 809026001
5. Schering AG, Novartis Pharma AG. PTK/ZK CONFIRM 1 Phase III Study Shows Positive Drug Effects in Metastatic Colorectal Cancer - Filing Now Anticipated for Early 2007. Media Release. : 21 Mar 2005. Available from: URL: http://www.schering.de. (English). 809046771
6. Novartis. Novartis/Schering AG Oral Angiogenesis Inhibitor PTK/ZK Completes Enrollment for Key Phase III Metastatic Colorectal Cancer Trial. Media Release. : 3 Jun 2004. Available from: URL: http:// www.novartis.com. (English). 809035481
7. Schering AG. Oral Angiogenesis Inhibitor Enters Phase III Trials for Treatment of Patients With Metastatic Colorectal Cancer. Media Release. : 2 Apr 2003. Available from: URL: http://www.schering.de. (English).
8. Schering AG, Novartis Pharma AG. Planned Interim Analysis of CONFIRM 2 Trial of PTK/ZK Indicates Low Probability of Demonstrating Overall Survival Benefit in Second-Line Therapy of Metastatic Colorectal Cancer. Media Release. : 28 Jul 2005. Available from: URL: http://www.schering.de. (English).
9. Schering AG. New Phase II Clinical Study of PTK/ZK in Lung Cancer. Media Release. : 2 Mar 2005. Available from: URL: http:// www.schering.de. (English). 809045949
10. Schroeder W, Abadie S, et al. Antiangiogenesis as new treatment modality in ovarian cancer: a phase Ib, open label, safety and pharmacokinetics study of escalating doses of PTK787/ZK222584 in combination with paclitaxel and carboplatin in patients with stage IC to IV epithelial ovarian cancer. EJC Supplements. 3: 273 (plus poster) abstr. 949, No. 2, Oct 2005. (English).
11. Pavel M, Schuppan D, et al. A phase I, open-label study with escalating doses of intravenous PTK787/ZK 222584, a multi-VEGF receptor inhibitor, followed by multiple oral daily dosing to assess the absolute bioavailability of PTK787/ZK 222584 after single and multiple doses in advanced cancer patients. EJC Supplements. 3: 427 (plus poster) abstr. 1474, No. 2, Oct 2005. (English).
12. Drevs J, Mross K, et al. Phase I dose escalation, pharmacokinetic study of a novel vascular endothelial growth factor receptor inhibitor, PTK787/ZK 222584. European Journal of Cancer. 35 (Suppl. 4): 283, Sep 1999. (English). 800771670
13. Yung WA, Friedman H, et al. A phase I trial of PTK787/ZK 222584, a novel oral VEGFR TK inhibitor in recurrent glioblastoma. 38th Annual Meeting of the American Society of Clinical Oncology. 21: 79, Part 1, 18 May 2002. (English). 800883518
14. Roboz GH, List AF, et al. Phase I trial of PTK787/ZK 222584, an inhibitor of vascular endothelial growth factor receptor tyrosine kinases, in acute myeloid leukemia and myelodysplastic syndrome. Blood. 100: 337, Part 1, 16 Nov 2002. (English). 800930484
15. George D, Michaelson D, et al. Phase I study of PTK787/ZK 222584 in metastatic renal cell carcinoma. 39th Annual Meeting of the American Society of Clinical Oncology. : 385 (plus poster) abstr. 1548, 31 May 2003. (English). 800947090
16. Drevs J, Mross K, et al. Phase I dose-escalation and pharmacokinetic study of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases. 39th Annual Meeting of the American Society of Clinical Oncology. : 284 (plus poster) abstr. 1142, 31 May 2003. (English). 800949391
17. Trarbach T, Thomas AL, et al. Preliminary phase I results of the oral, once-daily angiogenesis inhibitor PTK787/ZK 222584 in combination with chemotherapy for the treatment of metastatic colorectal cancer. EJC Supplements. 1: 91 (plus poster) abstr. 297, No. 5, Sep 2003. (English). 800955761
18. Vanhoefer U, Trarbach T, et al. Phase I/II study of PTK787/ZK 222584, a novel, oral angiogenesis inhibitor in combination with FOLFIRI as first-line treatment for patients with metastatic colorectal cancer. Annals of Oncology. 15 (Suppl. 3): 94-95 (plus poster) asbtr.352P, 2004. (English). 800983687
19. Drevs J, Hofmann I, et al. Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. Cancer Research. 60: 4819-4824, 1 Sep 2000. (English).
20. Wood JM, Bold G, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Research. 60: 2178-2189, 15 Apr 2000. (English).
21. Knoblich J, Paldanius PM, et al. Clinical results from an ADME (absorption, distribution, metabolism, and excretion) trial of PTK787/ZK 22284: a novel, oral angiogenesis inhibitor in patients with advanced cancer. EJC Supplements. 1: 170, No. 5, Sep 2003. (English).
22. Xu L, Herrera CA, et al. Therapy of VEGF-dependent human ovarian carcinoma by oral administration of CGP 79787/ZK222584, an inhibitor of the VEGF receptor tyrosine kinase. 90th Annual Meeting of the American Association for Cancer Research. : 457, 10 Apr 1999. (English). 800743129
23. Solorzano CC, Baker CH, et al. Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases. Cancer Biotherapy and Radiopharmaceuticals. 16: 359-370, Oct 2001. (English).
24. Lin B, Podar K, et al. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Research. 62: 5019-5026, 1 Sep 2002. (English).
25. Yung WKA, Friedman H, et al. A phase I trial of single-agent PTK 787/ZK 222584 (PTK/ZK), an oral VEGFR tyrosine kinase inhibitor, in patients with recurrent glioblastoma multiforme. 39th Annual Meeting of the American Society of Clinical Oncology. : 99 (plus oral presentation) abstr. 395, 31 May 2003. (English). 800897867
26. Reardon D, Friedman HS, et al. A phase I trial of PTK787/ZK 222584, an oral VEGF tyrosine kinase inhibitor, in combination with either temozolomide or lomustine for patients with recurrent glioblastoma multiforme. 39th Annual Meeting of the American Society of Clinical Oncology. : 103 (plus poster) abstr. 412, 31 May 2003. (English). 800897868
27. Drevs J, Steward WP, et al. Biomarkers (VEGF, BFGF) for assessing the biolgoical activity of PTK787/ZK222584, a vascular endothelial growth factor (VEGF) receptor inhibitor, in tumours known to overexpress VEGF. European Journal of Cancer. 38 (Suppl. 7): 78, Nov 2002. (English).
Go to the next page.
4-6
